Dosing & Uses
Fabry Disease
Pending FDA approval for Fabry disease
Next:
Pharmacology
Recombinant alpha-galactosidase A, an enzyme (deficient in Fabry disease) involved in the metabolism of glycosphingolipids (eg, GL-3); corrects abnormal glycosphingolipid metabolism resulting in reduced accumulation of glycosphingolipids and improvement of associated clinical manifestations (eg, vascular occlusion, stroke, renal failure, heart failure); reduces GL-3 deposition in capillary endothelium
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
